Asia-Pacific Algae Omega-3 Ingredients - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The asia-Pacific algae omega-3 ingredient market was valued at USD 345.16 million in 2025 and is forecast to reach USD 713.62 million by 2031, growing at a CAGR of 13.06% during 2026-2031. This report is Segmented by Type (Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), EPA/DHA Blends), Application (Food and Beverages, Dietary Supplements, Infant Formula, Pharmaceuticals, Clinical Nutrition, Others), and Geography (China, India, Japan, Australia, Rest of Asia-Pacific). The Market Forecasts are Provided in Terms of Value (USD Million).

Asia-Pacific Algae Omega-3 Ingredients Market Trends and Insights

Growing Preference for Plant-Based Nutrition

Plant-based nutrition has become a key demand driver for the Asia-Pacific algae omega-3 ingredient market, as more consumers in the region choose vegetarian, vegan, and sustainable nutrition products. Algae-derived omega-3 offers a direct alternative to fish-derived omega-3 and helps brands address concerns related to marine contamination, odor, taste, and limited supply chain transparency in fish oil. It also supports cleaner-label positioning, which is becoming important in supplements, infant nutrition, and functional food products. In China, supplement manufacturers are expected to increase the use of algal oil DHA in 2025, especially in children’s, maternal, and adult nutrition products. In India, the food regulator continues to review novel algae-derived ingredient filings in 2024, with related activity expected to continue into 2025. These developments are encouraging formulators to use algal DHA as a mainstream ingredient in supplements and infant nutrition rather than as a niche or specialist addition.

Sustainability Concerns Versus Fish Oil

Climate risks in the conventional fish oil supply are shaping sourcing decisions in the Asia-Pacific algae omega-3 ingredient market. Fish-based omega-3 supply depends on catch availability, which can change due to weather conditions and disruptions in fisheries. This volatility is encouraging infant formula and supplement manufacturers to reduce supply risk by using algae-derived DHA and EPA as an additional source. China is expected to export 1,200 metric tons of algal DHA oil in 2025, up 26.7%, reflecting growing confidence in its domestic fermentation capacity. In Australia, compositional guidance recognizes DHA-rich and DHA/EPA-rich Schizochytrium algal oils for listed medicines, supporting their use in regulated health products. These developments position algae oil as a reliable omega-3 supply source that is less dependent on fishery cycles.

Regulatory Hurdles for Novel Ingredients

Regulatory requirements vary across Asia-Pacific, making regional launch plans more complex in the Asia-Pacific algae omega-3 ingredient market. Each country follows a different approval process for ingredients, health claims, labeling, and product formats. Australia applies novel food rules and ingredient guidance, while India follows ingredient-specific approval pathways for new food formats. China is expected to have 142 validly registered DHA-class health food products by June 2026, with algae-sourced products accounting for 39.4%. Japan requires strong scientific substantiation for product claims, which can be challenging for mid-sized producers with limited clinical research budgets. As a result, companies cannot rely on one regulatory strategy for the entire region. These differences can delay product launches, increase compliance costs, and raise the value of suppliers that already hold approvals across multiple countries.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Functional Foods and Supplements
• Growth in Prenatal and Maternal Nutrition
• Intellectual Property and Strain Patent Barriers

Segment Analysis

DHA accounted for 43.5% of the Asia-Pacific algae omega-3 ingredient market size in 2025. Its position rests on infant formula, cognitive-health supplements, and maternal nutrition. China’s infant formula requirements increase the need for consistent, high-purity DHA inputs. Fermentation-controlled algal DHA also addresses concerns about contaminants associated with fish-derived materials. CABIO Biotech produces algal DHA as oil, microcapsule powder, and biomass powder from its Wuhan operations. These formats serve the infant formula and supplement applications that support DHA demand.

EPA/DHA blends are projected to grow at a CAGR of 14.2% from 2026 to 2031, the fastest rate among product types. Fermentalg launched OMEGA ΩRIGINS EPA/DHA in April 2026 using its Schizochytrium sp. FCC-3204 fermentation process. The product provides 40% EPA and 20% DHA without a concentration step. Blended formulations respond to demand for cardiovascular and neurodevelopmental positioning in one ingredient. EPA-only algal oils occupy a smaller but developing role in clinical nutrition and pharmaceutical applications. NTT reported in July 2026 that it had bred diatom strains with higher DHA, EPA, and other functional fatty acids, with concentrations up to 1.8 times the parent strain. This work points to future production methods that improve the fatty-acid profile at the biomass stage.

Complete Report Scope:

• By Type
  • Eicosapentaenoic Acid (EPA)
  • Docosahexaenoic Acid (DHA)
  • EPA / DHA Blends
• By Application
  • Food and Beverages
  • Dietary Supplements
  • Infant Formula
  • Pharmaceuticals
  • Clinical Nutrition
  • Others
• By Geography
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

List of Companies Covered in this Report:

• dsm-firmenich
• Corbion N.V.
• CABIO Biotech
• Archer Daniels Midland Company
• BASF SE
• Polaris SA
• Veramaris V.O.F.
• Fermentalg SA
• Mara Renewables Corporation
• Qualitas Health
• Cellana Inc.
• Algatechnologies Ltd.
• AlgaeCytes Ltd.
• Solutex GC S.L.
• Neptune Wellness Solutions Inc.
• Nordic Naturals Inc.
• Novotech Nutraceuticals Inc.
• Qponics Limited
• Xiamen Huison Biotech Co. Ltd.
• SIMRIS ALG AB
• Cargill Incorporated
• ADM Onavita

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support